INTRODUCTION {#S1}
============

Multiple lines of evidence provide strong support for a genetic basis for autism spectrum disorders (ASD). *De novo* mutations, originating primarily in the parental germline, are individually rare but their collective risk is substantial and accounts for an estimated 30% of simplex ASD cases^[@R1],[@R2]^. To date, most of the emphasis on identifying high-impact risk variants has focused on establishing burden for likely gene-disruptive (LGD) mutations (nonsense, frameshift, or splice-site)^[@R3]--[@R5]^. High-impact risk genes with primarily *de novo* missense mutations have been understudied because a much smaller fraction (13%) are thought to be pathogenic when compared to *de novo* LGD mutations (42%)^[@R1]^. Moreover, *de novo* missense mutations are eightfold more common making it more challenging to prove their statistical relevance. Notwithstanding, a comparison of mutation rates in individuals with ASD and their unaffected siblings reveals that missense mutations contribute to disease risk in as many, if not more, cases than LGD mutations (12% vs. 9%, respectively)^[@R1]^.

The identification of genes with a significant burden of missense mutations, then, is likely to highlight new classes of neurodevelopmental disorder (NDD) risk genes. In some cases, this may reflect genes with such critical functions that LGD mutations are incompatible with life^[@R1],[@R6]^. In other cases, the mutation's effect on the protein may differ. For example, missense mutations are more likely to have a gain-of-function effect^[@R7]^ when compared to LGD mutations, which are predominantly loss-of-function. Clustering of missense mutations may highlight important and even novel functional domains, providing insight into ASD pathogenesis and future downstream therapeutic targets. High-confidence ASD risk genes have been successfully identified by searching for mutation recurrence^[@R3],[@R4],[@R8],[@R9]^. Given that missense mutations are more common and \~90% of them are thought to be incidental^[@R1]^, a much larger sample size is required to prove pathogenicity. We took advantage of the significant phenotypic and genotypic overlap between ASD, developmental delay (DD) and intellectual disability (ID), epilepsy, congenital heart disease, and schizophrenia^[@R10]^ to study the pattern and distribution of *de novo* missense mutations more broadly. We focused on clustered and recurrent site mutations and tested a larger cohort of affected children to identify pathogenic events and implicate new missense "hotspot" genes in NDD pathogenesis.

RESULTS {#S2}
=======

Properties of *de novo* missense mutations in NDD patients {#S3}
----------------------------------------------------------

We began by assessing the rates of *de novo* missense mutation in cases and controls. We identified a total of 5,807 *de novo* missense mutations in cases (n = 8,477) and 1,475 such events in controls (n = 2,178) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The fraction of probands with one or more event (50.7%) is significantly greater than the fraction of controls (47.8%; p = 0.016, OR = 1.12 \[1.02--1.24\], two-sided Fisher's exact test) ([Fig. 1a](#F1){ref-type="fig"}). As there were over three times as many cases as controls, we sought to limit the possibility that the signal is driven by rare outliers in cases and thus applied a secondary test, downsampling cases to match the number of controls. This further confirmed a significant increase in the rate of *de novo* missense mutations in cases (one-tailed empirical p = 9.22×10^−4^, OR = 1.12 \[1.06--1.19\], 1×10^6^ permutations) ([Fig. 1a](#F1){ref-type="fig"}). While the odds ratios for these two tests are nearly identical, the Fisher's exact test is considered more conservative and the hypergeometric distribution generates a wider confidence bound for the odds ratio when compared to that obtained by simulation.

Out of 4,227 genes with rare *de novo* missense mutations in cases, 974 (23.0%) harbor mutations in two or more unrelated cases ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). In contrast, among controls, 101 out of 1,362 genes (7.4%) are mutated recurrently ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Matching the number of cases and controls, we observe a significant increase in the number of genes among cases with two or more (one-tailed empirical p = 0.011, OR = 1.26 \[1.10--1.42\], 1×10^6^ permutations) and three or more (one-tailed empirical p = 3.10×10^−5^, OR = 3.13 \[2.22--4.03\], 1×10^6^ permutations) *de novo* missense mutations ([Fig. 1b](#F1){ref-type="fig"}). The increased recurrence rate is not explained by increased mRNA or protein length, as genes with recurrent mutations in cases are significantly shorter than those with recurrence in controls (mRNA, p = 5.19×10^−3^; protein, p = 1.47×10^−3^; two-sided Wilcoxon rank-sum tests). Additionally, the total number of genes with mutations is smaller among cases (1,323 in downsampled cases vs. 1,362 in controls), suggesting that mutations in cases are not randomly distributed but rather cluster within fewer genes.

We next compared the severity of *de novo* missense mutations between cases and controls by assessing the Combined Annotation Dependent Depletion (CADD) score^[@R11]^. The CADD score distribution is significantly positively skewed in cases compared to controls consistent with an increase in deleteriousness (p = 2.2×10^−4^, two-sided Wilcoxon rank-sum test). Further, at increasing minimum CADD score thresholds, the likelihood that an observed event can be attributed to a case increases ([Fig. 2a](#F2){ref-type="fig"}). At a CADD threshold of 28, the likelihood rises dramatically (\>1.2 positive likelihood ratio). Importantly, mutations in genes with higher levels of recurrence in cases also show significantly higher CADD scores (p = 5.87×10^−29^, F = 45.12, 3 degrees of freedom, one-way ANOVA), indicating that recurrence and severity are both valuable markers of missense pathogenicity and that they are highly correlated ([Fig. 2b](#F2){ref-type="fig"}).

Genes with recurrent missense mutations {#S4}
---------------------------------------

To further assess gene-specific recurrent mutations, we applied a probabilistic model that calculates the expected number of mutations in a gene, based on locus- and base-specific relative substitution rates^[@R12],[@R13]^ (see Methods). We identified 35 genes that had significantly more *de novo* missense mutations in cases than expected (false discovery rate (FDR) \< 5%) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Only two genes, *YIF1A* and *PHKA2*, reached significance in controls ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). For 17 of the genes significant in cases, an excess of loss-of-function mutation has already been established by copy number variants (CNVs) and LGD mutation (e.g., *GRIN2B, PTEN*, and *SCN2A*^[@R14]--[@R16]^). For 13 of the remaining significant genes, no LGD mutations have been identified in the 24 cohorts studied here or in individuals with NDD in the Online Mendelian Inheritance in Man \[OMIM; <http://omim.org/>\] or ClinVar \[<https://www.ncbi.nlm.nih.gov/clinvar/>\] databases. While six of these missense-only genes are well known and associated with specific phenotypes (e.g., *PACS1* and Schuurs-Hoeijmakers syndrome^[@R17]^), the remaining seven warrant additional follow-up.

As a set, the 35 genes with excess *de novo* missense mutations are enriched for aspects of neuronal communication such as postsynaptic membrane potential regulation (6 observed vs. 0.17 expected, 35.3-fold enrichment, p~adj~ (Bonferroni corrected) = 1.61×10^−4^, two-sided binomial test) and synaptic signaling (8 observed vs. 0.7 expected, 11.4-fold enrichment, p~adj~ = 3.30×10^−3^, two-sided binomial test), nervous system development (16 observed vs. 3.7 expected, 4.4-fold enrichment, p~adj~ = 1.05×10^−3^, two-sided binomial test), and gene expression regulation (3 observed vs. 0.03 expected, \>100-fold enrichment, p~adj~ = 2.42 × 10^−2^, two-sided binomial test). There is also significant enrichment for genes involved in the presynapse (5/336 genes; p = 3.74×10^−4^, OR = 9.25 \[3.40-Inf\], one-sided Fisher's exact test) and postsynaptic density (11/1,755 genes; p = 2.17×10^−4^, OR = 4.50 \[2.26-Inf\], one-sided Fisher's exact test), and targets of FMRP (14/842 genes; p = 1.20×10^−10^, OR = 14.37 \[7.57-Inf\], one-sided Fisher's exact test).

In addition to recurrent mutations within the protein-coding portion of genes, we also assessed amino acids in which two or more *de novo* missense mutations in unrelated individuals with NDDs have been identified, hereafter referred to as sites. We identified 40 sites in 36 genes, 10 of which have a significant burden of *de novo* missense mutation, after excluding mutations observed in population controls (minor allele frequency (MAF) \> 0.01% in the Exome Sequencing Project (ESP; NHLBI GO ESP Exome Variant Server, Seattle, WA (<http://evs.gs.washington.edu/EVS/>) \[August 2016\]) (n = 6,503) or the Exome Aggregation Consortium^[@R18]^ (ExAC) database v.0.3 without neuropsychiatric disorders (n = 45,376)) ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). None of these mutations were observed in unaffected controls in denovo-db v.0.9. Seven sites had more than two recurrent mutations (e.g., *PACS1* with six mutations at residue 203) and some genes had more than one recurrently mutated amino acid residue (e.g., *SCN2A*). Sixteen of the amino acid sites involved adjacent mutations in the same codon. Twenty-eight of the 40 sites (36/56 mutations) involve CpG dinucleotides, consistent with their known association with hotspots of single-nucleotide variation^[@R19]^. Thirty-four sites had average CADD scores of 20 or greater and 17 had a score over 30, indicating that they are in the top 1% of deleterious mutations in the human genome. This observation stands in contrast to the pattern of *de novo* recurrent missense in controls, where only one of the three sites had a CADD score greater than 20, although the number of events compared is few.

Targeted sequencing of missense mutations {#S5}
-----------------------------------------

Using single-molecule molecular inversion probes (smMIPs), we targeted 20 of these recurrent sites for sequencing in a large cohort of 17,689 patients with a primary diagnosis of ASD or DD (including ID; [Supplementary Tables 5 and 6](#SD1){ref-type="supplementary-material"}). The set included primarily patients with idiopathic NDDs not yet tested by exome sequencing. We also included a set of unaffected siblings as an additional control (n = 3,023). We identified and validated 21 recurrent missense variants at 12 sites in 11 genes among cases ([Table 1](#T1){ref-type="table"}, [Fig. 3a--c](#F3){ref-type="fig"}). No variants were observed at any of the 20 sites in controls. The inheritance status for only eight of the variants identified in cases could be determined due to missing parental DNA---six were determined to be *de novo* missense mutations ([Table 1](#T1){ref-type="table"}; PACS1 p.Arg203 (two mutations), GRIA1 p.Ala636, SCN2A p.Arg937, and SMAD4 p.Ile500 (two mutations)). Interestingly, one of the inherited mutations (PTPN11 p.Gly503) is adjacent to the well-known Noonan syndrome recurrent mutation^[@R20]^ (PTPN11 p.Ser502) and was transmitted paternally to two children both affected with ASD and ID. No information on the father's phenotype is currently available. Five genes corresponding to six sites were identified with two or more recurrent missense mutations in the NDD cohort, namely GRIA1 p.Ala636, PACS1 p.Arg203, SCN2A p.Arg379, SCN2A p.Arg937, SMAD4 p.Ile500, and ZNF215 p.Arg473. Phenotypic similarities are present in patients with shared mutations, such as ALG13 ([Fig. 3b](#F3){ref-type="fig"}), where all six individuals with a mutation at residue 107 have both EPI and DD even though they were recruited from cohorts with different primary diagnostic criteria. Both individuals with newly found mutations at SMAD4 p.Ile500 have features consistent with Myhre syndrome, including ID, short stature, facial dysmorphisms, and hearing loss^[@R21],[@R22]^ ([Supplementary Clinical Case Reports](#SD3){ref-type="supplementary-material"}).

We also observed rare, potentially disruptive, missense variants in close proximity to the original recurrent site mutations, such as in *SMAD4* ([Fig. 3c](#F3){ref-type="fig"}). We reexamined our database for regions where multiple recurrent *de novo* missense mutations mapped within 10 amino acids. We designed smMIPs for 17 clustered regions as well as the 20 recurrent sites (in 30 total genes) and sequenced this extended set (\~5 kbp of coding sequence) in a subset of the NDD cohort ([Supplementary Tables 5 and 6](#SD1){ref-type="supplementary-material"}). Combined with targeted sites, we discovered a total of 139 recurrent or clustered missense variants in 137 cases compared to seven variants in five unaffected siblings, representing a significant enrichment (p = 1.11×10^−4^, OR = 3.93 \[1.76--10.89\], two-sided Fisher's exact test) ([Table 2](#T2){ref-type="table"} and [Supplementary Table 7](#SD1){ref-type="supplementary-material"}). Twelve of the clustered missense mutations in cases were confirmed *de novo*, including events in *SATB2* ([Fig. 3d](#F3){ref-type="fig"}), *GRIA1* ([Fig. 4a](#F4){ref-type="fig"}), *SCN2A, KCNQ3, SCN8A, DEAF1*, and *PPR2R1A* ([Supplementary Table 8](#SD1){ref-type="supplementary-material"}).

In addition to new variants at sites in denovo-db v.0.9, targeted sequencing established 14 new sites, although inheritance status for most variants remains unknown. The specific variants at SCN8A p.Arg1617 and STXBP1 p.Arg551 have been seen previously in NDD cases. While Myhre syndrome has been associated only with residue 500 of SMAD4^[@R22]^, *in silico* predictions suggest that the p.Arg496Cys mutations we identified are also likely to be pathogenic as the residue is highly conserved across species and the amino acid substitution is nonconservative^[@R23]^. Detailed phenotypic information on one patient with this mutation indicates characteristics of the syndrome, including ID, short stature, and dysmorphic facial features, suggesting that Myhre syndrome is not only limited to one codon^[@R22]^. Phenotypic commonalities are also present amongst individuals with clustered mutations, indicating the functional relevance of protein domains. For example, seven out of eight patients with a mutation in the first DNA binding domain of SATB2 ([Fig. 3d](#F3){ref-type="fig"}) have facial dysmorphisms and seven out of eight have DD.

*De novo* missense mutations in *GRIA1* {#S6}
---------------------------------------

We identified a recurrently mutated amino acid in *GRIA1* (a.k.a. GluA1; [Fig. 4a](#F4){ref-type="fig"}), a subunit of AMPA glutamate receptors, which was originally reported in one patient with ID^[@R24]^ and another with ASD^[@R14]^. Both patients share an identical *de novo* G\>A mutation resulting in an alanine to threonine amino acid replacement at residue 636 (NP_000818.2). Resequencing identified the same variant in three more patients with a primary diagnosis of ASD. One newly found mutation was confirmed as *de novo*; paternal DNA is not available for the other two but the mutation is not present in either of the patients' mothers. Using array comparative genomic hybridization, we found no evidence for large pathogenic CNVs in any of the three patients for whom we had DNA. While this position is a CpG dinucleotide and therefore prone to recurrent mutation, this variant has not been observed in 60,706 individuals published by ExAC^[@R18]^. Moreover, we identified a second *de novo* missense mutation in close proximity ([Fig. 4a](#F4){ref-type="fig"}) in a patient with DD. The dearth of variants in healthy controls and the observation of the same recurrent variant in six unrelated patients (three of which were *de novo* (p = 5.39×10^−3^, one-tailed binomial test, genome-wide correction)) suggested that the mutation was pathogenic.

The mutated site maps to the eighth position (p.Ala636) of a highly conserved 9-amino acid motif, SYTANLAAF ([Fig. 4b](#F4){ref-type="fig"}), present in the M3 transmembrane domain of all glutamate receptors, which plays a critical role in channel gating^[@R25]^. The specific alanine to threonine mutation observed in the six patients here has been observed at the functionally equivalent site in other members of the glutamate receptor gene family. It was first identified as a spontaneous mutation in *Grid2* in a mouse line at Jackson Laboratories (Lurcher) that results in a constitutively active channel comprised of homomeric GluRδ2 subunits selectively expressed in cerebellar Purkinje neurons^[@R26]^. Mice heterozygous for this mutation in the GluRδ2 receptor develop severe ataxia as a consequence of neurotoxicity from excess current flux. Notably, humans with the mutation in GluRδ2 also suffer from ataxia^[@R27]^. Engineering of the A\>T mutation at the homologous site in the rat isoform of the GluA1 receptor produces a similar constitutively active phenotype with altered kinetic and pharmacological properties^[@R28]--[@R30]^.

To confirm constitutive activity or leak current in the human isoform of *GRIA1* identified in affected patients, we synthesized cDNA encoding the human wild-type (WT) and mutant (A636T) at base-pair position 1906 (G/A). Leak current was measured using whole-cell voltage-clamp recordings of HEK 293 cells heterologously expressing either WT or A636T in the absence of agonist by applying a voltage ramp from −100mV to +80mV. GluA1-mediated current was confirmed by application of the AMPA receptor-selective antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo\[f\]quinoxaline-2,3-dione (NBQX), followed by an additional voltage ramp. Subtracted current in the presence of NBQX revealed a notable constitutive current in A636T, but not WT-expressing cells ([Fig. 4d,f](#F4){ref-type="fig"}). Consistent with GluA1-mediated current, inward rectification is abolished following channel blockade with NBQX. No changes in current magnitude or shape were seen in cells expressing the WT channel after NBQX application ([Fig. 4c,f](#F4){ref-type="fig"}). Affected patients with the p.Ala636Thr mutation are heterozygous indicating that a majority of receptors are likely comprised of WT and p.Ala636Thr receptor subunits. To assess the functional phenotype of these 'heteromeric' receptors, we co-transfected equal ratios of WT and A636T DNA and performed the same voltage-ramp recordings ([Fig. 4e](#F4){ref-type="fig"}). While a noticeable constitutive current was still present, it was smaller than the homomeric p.Ala636Thr channel demonstrating that the overall effects of the mutation are mitigated by the presence of the WT subunits ([Fig. 4f](#F4){ref-type="fig"}).

Consistent with the prevalent role of GluA1 homomeric channels in synapse development and synaptic plasticity^[@R31]^, phenotypic analysis of four of the individuals with the A636T mutation demonstrates common features ([Supplementary Table 9](#SD1){ref-type="supplementary-material"}), including mild to moderate ID (4 of 4 individuals) and ASD (3 of 4 individuals). Three of the four for whom information is available had delayed language development, with two (both with ASD) demonstrating persistent difficulties with pronunciation and vocabulary. These two individuals were also noted to have highly similar facial features and were diagnosed with ADHD. Similarly, the individual without ASD is noted to have behavioral dysfunction. Two individuals also had delayed motor development. All four have normal MRIs. Collectively our evidence suggests that this specific missense mutation dictates a common pathological brain development trajectory and supports the idea that specific missense mutations contribute to NDD pathogenesis.

Clustered missense mutations and functional domains {#S7}
---------------------------------------------------

Our sequencing results as well as the *GRIA1* analysis strongly suggest that clustered and recurrent missense mutations have the potential to highlight functional protein domains important in NDD pathology. We previously developed a tool, CLUMP^[@R7]^, to assess the significance of clustered mutations and we applied it to an updated version of denovo-db (v.1.2) to identify genes and functional domains for future investigation. Overall, we examined 8,917 *de novo* missense mutations in cases and calculated raw CLUMP scores for 1,699 proteins containing at least two mutations in cases. We performed case--control analyses comparing the pattern of private alleles in ExAC and separately among European individuals from the 1000 Genomes Project or 1KG (see Methods). Twenty-eight out of 34 genes we initially identified were testable by this approach and 18 of them showed nominally significant clustering of *de novo* missense mutations (p \< 0.05, CLUMP, one-tailed permutation test). Altogether, we identified 200 genes with significant clustering of missense mutations at the protein level ([Supplementary Table 10](#SD1){ref-type="supplementary-material"}). Once again, this set is significantly associated with aspects of neuronal communication, including regulation of the postsynaptic potential (11 observed vs. 1 expected, 11.0-fold enrichment, p~adj~ = 6.93×10^−5^, two-sided binomial test) and synaptic signaling (20 observed vs. 4.15 expected, 4.82-fold enrichment, p~adj~ = 8.38×10^−5^, two-sided binomial test), as well as chromatin-mediated maintenance of transcription (4 observed vs. 0.1 expected, 40.7-fold enrichment, p~adj~ = 2.96×10^−2^, two-sided binomial test). Many of the genes encode channel proteins and receptors (e.g., *GRIA1, GRIN1, GRIN2A, GRIN2B, KCNH1, KCNQ2*) and exhibit clustering in or near specific functional domains, such as the transmembrane, pore or voltage sensor domains ([Fig. 5a--d](#F5){ref-type="fig"}). Other proteins, such as CTCF, are remarkable in that the clustering pattern of patient missense mutations highlights a subset of the C2H2 ZNF motifs, which are never mutated in controls ([Fig. 5e](#F5){ref-type="fig"}). These pockets of patient-only missense mutations will be increasingly important in characterizing pathogenic genes and functional domains.

DISCUSSION {#S8}
==========

The objective of this research study was twofold: define the features of likely disease-causing *de novo* missense mutations and identify new genes and functional domains relevant to the pathology of NDDs. To increase sample size, we broadly defined NDDs to include not only data from patients with ASD, DD, and ID but also patients with epilepsy and schizophrenia due to the extensive comorbidity of these diagnoses. As expected, both recurrence and severity of missense mutations are critical features. The likelihood of a pathogenic mutation rises significantly when three or more missense mutations are observed in a gene (p = 1.06×10^−18^, two-sided Wilcoxon rank-sum test) and, in particular, when the severity of the missense mutation exceeds a CADD score of 28 (\>1.2 positive likelihood ratio). We use these features to identify 35 genes with an excess (q \< 0.05) of *de novo* missense mutations ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Targeted sequencing of specific protein-coding regions shows that recurrent and clustered amino acid replacements are more common in cases than controls (p = 1.11×10^−4^, OR = 3.93 \[1.76--10.89\], two-sided Fisher's exact test). While many of the top-scoring genes are associated with known syndromic and non-syndromic forms of NDD (e.g., *SCN2A* with ASD^[@R32]^, *PACS1* with Schuurs-Hoeijmakers syndrome^[@R17]^, and *ALG13* with epilepsy^[@R33]^), seven of these candidates have not been previously reported in ClinVar or OMIM. We also identify 200 genes with patterns of *de novo* missense mutations that are more clustered in cases when compared to population controls ([Supplementary Table 10](#SD1){ref-type="supplementary-material"}), 79% (n = 157) of which have not yet been associated with an NDD in OMIM or ClinVar databases.

Among the 35 genes with a significant excess of recurrent missense mutations, 37% (n = 13) have not yet been associated with a *de novo* LGD mutation (e.g., *COL4A3BP, PPP2R5D*) suggesting that LGD events are either not tolerated or associated with a different diagnostic outcome. In support of this observation, 71% (n = 25) of genes were also recently highlighted as likely pathogenic in an exome sequencing study of 3,287 individuals with DD^[@R15]^. Of the 200 genes with significant clustering of missense mutations, 67% (n = 134) did not show any evidence of LGD mutation in NDDs in denovo-db v.1.2, OMIM, or ClinVar; 45% (n = 89) have been shown to be loss-of-function intolerant in the ExAC database^[@R18]^, suggesting that LGD mutations in them may be genetically lethal (e.g., cause embryonic lethality or infertility), although additional experiments will be required to make this determination. In many cases, the clustering of *de novo* mutations highlights protein functional domains ([Fig. 5](#F5){ref-type="fig"}), such as specific zinc-finger motifs (e.g., *CTCF*), transmembrane domains (e.g., *GRIN1*), and voltage sensors and channel pores (e.g., *KCNQ2*). As the number of exomes increases, these hotspots of pathogenic missense mutation will become more transparent and may be better understood in the context of protein structure. *PTPN11*, associated with Noonan syndrome^[@R20]^, is predicted, for example, to have three clusters by CLUMP and 3D protein structure analysis reveals that these three clusters define the cleft of the ligand binding site^[@R34]^ ([Supplementary Fig. 1](#SD2){ref-type="supplementary-material"}).

It is interesting that genes associated with hotspots of missense mutation ([Supplementary Table 10](#SD1){ref-type="supplementary-material"}) are particularly enriched for presynaptic active zone proteins, FMRP-binding targets, and covalent chromatin modification, although not CHD8 target genes. Accumulating evidence supports a link between the development and function of excitatory synapses in NDD and ASD^[@R35]^. Consistent with this, we find 35-fold and 11-fold enrichments of genes regulating postsynaptic membrane potential in genes that carry a significant burden and genes with significant clustering of *de novo* missense events, respectively. While several scaffolding and intracellular signaling proteins have been associated with ASD and disruption of synaptic function, including SH3 and multiple ankyrin repeat domain (SHANK) proteins^[@R36]^, synaptic Ras GTPase-activating (SYNGAP) proteins^[@R37]^, neurexins^[@R38]^, neuroligins^[@R39]^, and others^[@R35]^, a functional mutation in an essential pore-forming subunit of an excitatory ionotropic glutamate receptor has not been described to our knowledge.

The fact that five patients with phenotypic similarity were identified with a gain-of-function p.Ala636Thr mutation strongly supports a role for *GRIA1* in ASD and related NDDs. This specific *de novo* missense mutation has been observed before at the homologous position in a highly conserved motif in a different glutamate receptor, GluRδ2^[@R26]^. The mutation has a gain-of-function effect, causing constitutive channel opening, neurotoxicity, and degeneration of the cerebellar Purkinje cells in which GluRδ2 is selectively expressed^[@R40]^. Both mice and humans with this mutation in GluRδ2 develop ataxia as a direct consequence^[@R27]^. This mutation in rodent GluA1 (the product of *Gria1*) has the same effect on channel gating^[@R29],[@R30]^, and here we have replicated this finding in human GluA1. As GluA1 plays an important role in learning and memory^[@R31]^, there is a biologically plausible link between this *de novo* missense mutation in *GRIA1* and ID.

*GRIA1* has been demonstrated to play a key role in early synapse development, with GluA1 homomeric channels being inserted into nascent synapses to provide a calcium-permeable, high-conductance channel prior to being replaced by GluA2-containing channels that mediate long-term synaptic connectivity. Continuing into adulthood, long-term potentiation of excitatory synapses, associated with learning and memory, requires initial insertion of GluA2-absent, calcium permeable AMPA receptors followed by replacement with GluA2-containing receptors^[@R31]^. The developmental and adult function of GluA1 in these contexts likely contributes to the ID associated with this mutation. It is interesting to note that loss-of-function of GluA1 in *Gria1* knockout mice leads to impaired synaptic function^[@R41]^ and behavioral phenotypes, including social behavior deficits and impulsivity^[@R42]^, which suggests that bidirectional aberration in excitatory signaling can result in similar ASD and NDD phenotypes. Future studies investigating the impact of the gain-of-function, Lurcher-like p.Ala636Thr mutation in synapse development and function will shed additional light on how alterations in excitatory synaptic function contribute to ASD.

ONLINE METHODS {#S9}
==============

Exome datasets and missense mutation annotation {#S10}
-----------------------------------------------

We initially analyzed all *de novo* missense mutations available from 24 published cohorts^[@R1],[@R13],[@R14],[@R24],[@R32],[@R33],[@R43]--[@R63]^ of *de novo* mutations in individuals with NDDs (denovo-db v.0.9; [Supplementary Table 11](#SD1){ref-type="supplementary-material"})^[@R64]^. The NDD set included 8,477 individuals diagnosed with ASD, DD, ID, epilepsy (EPI), schizophrenia (SCZ), and congenital heart disease (CHD) as well as four cohorts of unaffected controls^[@R1],[@R47],[@R65]^ (n = 2,178) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Only CHD patients from Homsy et al. (2015) with a secondary diagnosis of NDD were included in this study; we also excluded unaffected siblings of ASD patients as controls if they had a Social Responsiveness Scale (SRS) score ≥60 to remove controls on the autism spectrum^[@R66]^. Variants were annotated with SeattleSeq^[@R67]^ version 138, which provides annotation for all available RefSeq transcripts in GRCh37/hg19. In the case of multiple transcripts, we selected the transcript for which the majority of missense mutations were annotated in both cases and controls. All *de novo* missense mutations were either previously validated or investigators relied on a high (\>95%) validation rate in a subset of mutations to ensure specificity. As some individuals with ASD were assayed as part of multiple cohorts, we took care to remove any duplicate entries. When possible, we compared the global identifier given to the samples that were housed at Rutgers (RUID). Three duplicate entries were found in this manner. For other shared mutations in ASD cohorts, we performed PCR amplification and Sanger sequencing on in-house DNA samples to confirm secondary variants. Five out of six pairs tested (two ASC \[Autism Sequencing Consortium\]-SSC \[Simons Simplex Collection\] pairs and three ASC-TASC \[The Autism Simplex Collection\] pairs) shared a second variant and we therefore assumed them to be duplicates. The presence of uniquely identifying secondary site mutations was also used to eliminate potential duplicates for globally dispersed samples. We excluded high-frequency mutations (MAF \> 0.1%) observed in NHLBI GO ESP Exome Variant Server (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (<http://evs.gs.washington.edu/EVS/>) \[August 2016\]).

Statistical analyses {#S11}
--------------------

Wherever possible, non-parametric tests were used. Data collection and analysis were not performed blind to the conditions of the experiments. Burden was compared between cases and controls for rare (MAF \< 0.1% in ESP) *de novo* missense mutations. Comparisons in rate of mutation and gene recurrence were made using two-sided Fisher's exact tests. For comparisons of mutation rate and recurrence that depended on identical numbers of cases and controls, we performed one million downsamplings and used permutation tests, reporting the empirical p-values. Data distribution was assumed to be normal but was not formally tested. To identify significant enrichments for missense mutations within genes and genic regions, we applied a probabilistic model that incorporates sequence context and human--chimpanzee fixed differences to generate a null model for the distribution of missense variation across the genome and applied a one-tailed binomial test to test for enrichment^[@R13]^. For examination of individual codons and specific target regions, we applied the same method but restricted to the sequence context of the target region and normalized by the gene-specific human--chimpanzee divergence. For all tests we assumed a mutation rate of 1.8 *de novo* coding variants per generation^[@R12]^. Multiple testing corrections were applied using two paradigms based on the analysis type. For significance calculations of whole genes, we utilized the Benjamini-Hochberg FDR correction based on an estimated 19,000 genes in the human genome^[@R68]^ and report the q-values for each test. For codon analysis we applied the conservative Bonferroni family-wise error rate (FWER) correction based on the number of amino acids in the genome (n = 1.1×10^7^) to generate genome-wide significance estimates and report the adjusted p-value (p~adj~). Gene ontology enrichment was assessed using PANTHER (database 2017-04-13) for GO biological process annotation and corrected for multiple testing (Bonferroni, reported as p~adj~). We also applied a one-sided Fisher's exact test for testing the enrichment of specific gene sets, including neuronal compartments such as the post-synaptic density^[@R69]^ and targets of CHD8^[@R70]^ and FMRP in brain tissue^[@R71]^.

Targeted sequencing {#S12}
-------------------

smMIPs^[@R72]^ were designed with the MIPgen program^[@R73]^ to capture sequences of interest. To maximize coverage, we designed one smMIP for each strand for each target. We first used smMIPs targeting 24 sites to sequence eight cohorts containing a total of 6,058 cases and 2,854 controls. We also used smMIPs targeting two amino acids thought to be sites (amino acids with *de novo* missense mutations in two or more unrelated individuals with NDD) but later discovered to be duplicate database entries (*TBR1*) or present in both the case and her unaffected sister (*PDCD11*). As clusters of missense mutations have been associated with NDDs^[@R74]^, we then designed a set of smMIPs targeting 17 clusters in denovo-db v.0.9 ([Supplementary Table 11](#SD1){ref-type="supplementary-material"}). These cluster smMIPs, along with the 24 site smMIPs, were used on an additional four cohorts, containing 5,055 cases and 169 controls. A final set of smMIPs was created that excluded those targeting four sites that had no brain expression (*AGER, ZNF215*), low CADD scores (*ALDH5A1*), or high frequency in control populations (*DUSP15*). This final set, targeting 20 sites and 17 clusters, was used on five new cohorts, containing a total of 6,576 cases ([Supplementary Tables 5 and 6](#SD1){ref-type="supplementary-material"}). Across all three designs, this totals to 17,689 cases and 3,023 controls. The study size was not predetermined but based on the maximal number of samples that could be screened. Reads were aligned using BWA-MEM^[@R75]^ to GRCh37/hg19. All 146 rare (MAF \< 0.01%) variants with CADD score \>20 were validated with Sanger sequencing ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}). Patients were initially identified through targeted sequencing in anonymized ASD and DD cohorts. All patients were consented for sequencing and recontacting for inheritance testing at the providing laboratory. Patient samples were acquired from Adelaide (Jozef Gecz, University of Adelaide), Antwerp (Frank Kooy, University of Antwerp), Autism Clinical and Genetic Resources in China (ACGC; Kun Xia), the Autism Genetic Resource Exchange (AGRE), Iowa (Jacob Michaelson, University of Iowa), Leiden (Gijs Santen, Leiden University Medical Center), Leuven (Hilde Peeters, University Hospitals Leuven), Philadelphia (Hakon Hakonarson, Children's Hospital of Philadelphia), Prague (Zdenek Sedlacek, University Hospital Motol), San Diego (Eric Courchesne, UC San Diego), Simons Simplex Collection (SSC), Stockholm (Magnus Nordenskjold, Karolinska University Hospital), the Study of Autism Genetics Exploration (SAGE; Raphe Bernier, University of Washington), The Autism Simplex Collection (TASC), and Troina (Corrado Romano, Associazione Oasi Maria Santissima).

*GRIA1* transfection and patch-clamp recording assays {#S13}
-----------------------------------------------------

*GRIA1* wild-type and A636T mutant DNA sequences were synthesized (GenScript) and cloned into mammalian expression vectors. Human embryonic kidney (HEK) 293T/17 SF (ATCC ACS-4500) cells, routinely used for transient transfection and electrophysiological recordings as they allow robust heterologous expression, were cultured in DMEM (Invitrogen) supplemented with 10% Fetal Bovine Serum and 1% Streptomycin up to a maximum passage number of 15. For transient transfection, cells were split and plated onto 12 mm glass coverslips (Carolina Scientific) coated with Poly-L-Lysine (50 ng/µl). Then, 4--6 hours later, approximately 0.6 µg of total DNA/coverslip was transfected using the Fugene6 reagent (2 µl/coverslip, Promega). For heteromeric cells, approximately 0.3 µg of WT and A636T were co-transfected. Whole-cell recordings were performed approximately 60 hours after transfection using a Multiclamp 700B amplifier (Molecular Devices) with glass micropipettes of resistance 2--5 MΩ. Extracellular solution contained (in mM): 150 NaCl, 2.5 CaCl~2~, 2.5 KCl, 1 MgCl~2~, 10 D-Glucose, 10 HEPES, pH to 7.4 with NaOH. Intracellular pipette solution contained (in mM): 140 CsCl, 2 MgCl~2~, 10 HEPES, 10 EGTA, pH to 7.3 with CsOH. Voltage-ramp recordings ranged from −100mV to 80 mV and spanned 1.8 seconds. Data were collected with sampling at 10 kHz and only cells with whole-cell access resistance that remained less than 15 MΩ across recordings were included in analysis. To verify channel expression, a saturating concentration of glutamate (1 mM) was applied with 100 µM CX614, and only cells with detectable current were included. NBQX and CX614 were acquired from Tocris Biosciences. Sample size was chosen based on previous literature and variance of ion channel studies of similar nature.

Array comparative genomic hybridization {#S14}
---------------------------------------

Array labeling and hybridization was performed as previously described^[@R76]^. Briefly, 250 ng of sample DNA was labeled with Cy3 using a NimbleGen labeling kit (Roche). Reference DNA (NA12878) was labeled in a pooled reaction for four arrays with Cy5 using 1 ug of DNA. Hybridization was performed using the Agilent 2×400K array platform using standard reagents, imaged using an Agilent Scanner, and processed using Agilent Feature Extraction. CNV calls were generated using Agilent CytoGenomics 4.03.12 and the ADM2 calling algorithm with default parameters. For samples passing standard Agilent QC parameters (DLRSD \< 0.2), all CNVs over 100 kbp were visually inspected, filtered for known reference sample artifacts, and compared to 29,085 cases of ID/DD and 19,584 controls^[@R77]^ to identify rare CNVs that may contribute to pathogenicity in these cases.

Missense clustering {#S15}
-------------------

Genes with significant clustering of missense mutations were identified by CLUMP^[@R7]^ (CLUstering by Mutation Position; <https://github.com/karchinlab/clump>), which applies an unsupervised clustering algorithm based on partitioning around medoid distances between mutations. We implemented the permutation (−z 1000) and minimum mutation options (−m 2) and calculated a p-value based on the null distribution of case and control CLUMP score differences. The case set included individuals with an NDD primary phenotype (ASD, DD, ID, or EPI) from denovo-db^[@R64]^ v.1.2 ([Supplementary Table 11](#SD1){ref-type="supplementary-material"}) and consisted of 22 studies^[@R1],[@R12]--[@R14],[@R24],[@R32],[@R33],[@R43],[@R44],[@R48],[@R49],[@R51],[@R53]--[@R55],[@R57]--[@R62],[@R78]^ with 9,997 affected individuals (8,917 *de novo* missense variants). We compared against two control missense datasets: 1) missense mutations (MAF \< 1%) from Europeans^[@R7]^ (n = 420; 196,260 mutations) from the 1000 Genomes Project^[@R79]^ and 2) private missense mutations present in individuals from the ExAC v.0.3 without neuropsychiatric disorders (n = 45,376; 1,466,439 mutations)^[@R18]^. All variants were re-annotated using the CRAVAT software to enable exact transcript comparisons^[@R80]^.
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![Burden and recurrence of *de novo* missense mutations\
Bars for cases and controls represent observed data and error bars indicate the 95% confidence interval (CI) for the observed proportions (Clopper-Pearson method). Box-and-whisker plots for downsampled cases represent the distribution of one million permutations. Boxes show interquartile range (IQR) with lines at the median and whiskers are 1.5 times the IQR. Asterisks indicate p \< 0.05. **a)** 4,301 out of 8,477 cases (50.7%) and 1,042 out of 2,178 controls (47.8%) have one or more *de novo* missense mutations (denovo-db v.0.9) that are rare in the general population (MAF \< 0.1% in ESP). The fraction of individuals with one or more *de novo* missense mutation is significantly higher in cases (p = 0.016, OR = 1.12, two-sided Fisher's exact test) even after downsampling (empirical p = 9.22×10^−4^, OR = 1.12 \[1.06--1.19\]). **b)** The number of genes with two or more mutations in downsampled cases is significantly greater than controls (empirical p = 0.011, OR = 1.26 \[1.10--1.42\]), as is the number of genes with three or more mutations (empirical p = 3.1×10^−5^, OR = 3.13 \[2.22--4.03\]).](nihms879641f1){#F1}

![Severity of *de novo* missense mutations\
**a)** *De novo* missense mutations are more likely to be deleterious in cases (n = 5,807 mutations) versus controls (n = 1,475 mutations) and the positive likelihood ratio increases as severity increases (as measured by Combined Annotation Dependent Depletion (CADD) score). **b)** The distribution of CADD scores skews significantly as the number of *de novo* missense mutations per gene in cases increases (p = 5.87×10^−29^, one-way ANOVA) indicating an enrichment for genes with pathogenic mutations. Boxes show IQR with notches representing the 95% CI of the median; whiskers are 1.5 times the IQR. Circles are outliers.](nihms879641f2){#F2}

![Recurrent mutations fall in or near functional domains\
Published mutations in NDD patients are above the protein and new mutations identified by targeted sequencing are below the protein. *De novo* mutations (lightning bolt) and paternally inherited mutations (blue) are indicated. Inheritance is unknown for the remaining mutations. Protein domains are from UniProt.**a)** PACS1, NP_060496.2. **b)** ALG13, NP_060936.1. **c)** SMAD4, NP_005350.1. **d)** SATB2, NP_001165988.1.](nihms879641f3){#F3}

![Functional effect of recurrent GRIA1 missense mutations\
**a)** Linear representation of annotated domains in the protein GRIA1, a.k.a. GluA1 (NP_001244950.1) as defined in UniProt. **b)** A recurrent mutation observed only in NDD cases (n = 6 patients) falls within a highly conserved M3 transmembrane domain, important in channel gating. The alanine mutated in these patients (red) is homologous to the one that causes severe ataxia in Lurcher mice in the delta-2 subunit of this receptor (GRID2). **c--e)** Example current traces from a 1.8s voltage-ramp from −100mV to +80mV for **c)** WT, **d)** A636T, and **e)** heteromeric WT/A636T transfected HEK cells. The three current traces per panel correspond to voltage-ramp currents in the presence of normal extracellular solution (NaCl), extracellular solution supplemented with 50 uM NBQX (NBQX), and the isolated GluA1 dependent current determined by subtracting the NBQX current from the NaCl current (NaCl -- NBQX). **f)** Average leak current at −60mV. The GluA1-mediated current (NaCl -- NBQX) was determined at −60mV and averaged across cells (n = 5 (WT), 7 (A636T), and 5 (heteromeric); p = 0.024, F = 4.91, 2 degrees of freedom, one-way ANOVA). Data are mean +/− S.E.M.](nihms879641f4){#F4}

![Proteins with excessive clustering of missense mutations in NDD cases\
The pattern of *de novo* missense mutations in cases with NDDs is contrasted with rare missense variants from the 1000 Genomes Project (1KG) and private missense mutations from the Exome Aggregation Consortium (ExAC) excluding neuropsychiatric cases. Missense mutations are colored by severity (CADD heatmap) and recurrent *de novo* mutations at a specific amino acid position are indicated (triangle). Significance of clustering was calculated based on comparison to ExAC using CLUMP. **a)** GRIN1 (NP_001172019.1) shows greater missense mutation clustering in NDD patients (CLUMP = 1.68, p = 0.013) with region-specific significance corresponding to the transmembrane domains (amino acids 550--845; Fisher's exact test p = 5.6×10^−8^). **b)** Similarly, missense mutations cluster for GRIN2B (NP_000825.2; CLUMP = 1.34, p = 0.003) in particular between the second and fourth transmembrane domains (amino acids 600--820; p = 2.0×10^−9^). **c)** KCNK3 (NP_002237.1) patient missense mutations cluster (CLUMP = 0.54, p = 0.036) near the first transmembrane domain (amino acids 120--140, p = 9.4×10^−5^, OR = Inf). The average per-base rate of ExAC samples with ≥10× coverage across the exon harboring mutations in cases was 79.1%. **d)** KCNQ2 (NP_742105.1) shows several missense mutation hotspots (CLUMP = 0.36, p \< 1×10^−3^) corresponding to the pore and voltage sensor of the channel (amino acids 200--350, p = 2.0×10^−14^). **e)** Finally, patients show more severe CTCF (NP_006556.1) missense mutations that cluster (CLUMP = 1.0, p = 0.007) at two locations between the fourth and seventh C2H2 zinc finger motifs (amino acids 350--490, p = 9.1×10^−8^).](nihms879641f5){#F5}

###### 

New recurrent mutations at targeted missense sites.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene        Site       Alternate\   Protein ID       Mutations in\   Codon\        Codon *de novo* p,\                          Mutations identified with\                Total\       Codon\        Codon *de novo* p,\                          ExAC v.0.3\                
                         amino\                        denovo-db\      *de novo* p   genome-wide\                                 [smMIPs (N = 17850)]{.ul}                 *de novo*    *de novo* p   genome-wide\                                 allele count\              
                         acid(s)                       v.0.9 (N =\                   correction[\*](#TFN1){ref-type="table-fn"}                                                                        correction[\*](#TFN1){ref-type="table-fn"}   (N = 45376)                
                                                       8477)                                                                                                                                                                                                                   
  ----------- ---------- ------------ ---------------- --------------- ------------- -------------------------------------------- ----------------------------------------- ------------ ------------- -------------------------------------------- --------------- ---------- -------------------------------------
  *PACS1*     p.Arg203   Trp          NP_060496.2      6               1.03E-24      1.13E-17                                                                               2 (St, Tr)   1 (Ad)        8                                            1.37E-29        1.51E-22   1

  *PPP2R5D*   p.Glu198   Lys          NP_006236.1      4               3.84E-18      4.22E-11                                                                                            1 (Tr)        4                                            3.48E-16        3.83E-09   0

  *ALG13*     p.Asn107   Ser, Thr     NP_060936.1      5               5.26E-17      5.79E-10                                                                                            1 (Tr)        5                                            1.47E-14        1.62E-07   0

  *SCN2A*     p.Arg937   Cys, His     NP_001035232.1   3               9.47E-12      1.04E-04                                                                               1 (ACGC)     1 (ACGC)      4                                            8.26E-14        9.09E-07   0

  *SMAD4*     p.Ile500   Val, Thr     NP_005350.1      2               1.12E-07      1                                                                                      2 (An, Le)                 4                                            1.88E-13        2.07E-06   0

  *PTPN11*    p.Gly503   Arg, Glu     NP_002825.3      3               1.66E-11      1.83E-04                                     1[†](#TFN2){ref-type="table-fn"} (AGRE)                              3                                            5.10E-10        5.62E-03   0

  *GRIA1*     p.Ala636   Thr          NP_000818.2      2               1.11E-07      1                                                                                      1 (St)       2 (St)        3                                            4.89E-10        5.39E-03   0

  *SCN2A*     p.Arg379   His          NP_001035232.1   2               7.39E-08      8.14E-01                                                                                            1 (Ad)        2                                            7.04E-07        1          0

  *CLCN4*     p.Arg718   Trp, Gln     NP_001821.2      2               9.57E-08      1                                            1 (St)                                                               2                                            9.11E-07        1          0/2[††](#TFN3){ref-type="table-fn"}

  *KCNQ3*     p.Arg230   Cys          NP_004510.1      2               3.36E-07      1                                                                                                   1 (Tr)        2                                            3.20E-06        1          0

  *ZNF215*    p.Arg473   Gln          NP_037382.2      2               6.54E-07      1                                                                                                   3 (Ad)        2                                            3.49E-06        1          5

  *CUX2*      p.Glu590   Lys          NP_056082.2      2               5.38E-07      1                                                                                                   1 (Tr)        2                                            5.12E-06        1          0
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bonferroni family-wise error rate (FWER) correction based on 1.1E7 codons in genome.

In two affected siblings.

Allele in denovo-db v.0.9 has 0 occurrences in ExAC; allele found with smMIPs has been seen twice.

ACGC, Autism Clinical and Genetic Resources in China; Ad, Adelaide; AGRE, Autism Genetic Resource Exchange; An, Antwerp; Le, Leuven; St, Stockholm; Tr, Troina

###### 

Rare[\*](#TFN5){ref-type="table-fn"} clustered missense mutations identified by targeted sequencing (CADD \>20).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene         Site or cluster       Protein ID       denovo-\   [Controls]{.ul}   [Cases]{.ul}   [All cases]{.ul}[\*\*](#TFN6){ref-type="table-fn"}                            
                                                      db v.0.9                                                                                                                  
  ------------ --------------------- ---------------- ---------- ----------------- -------------- ---------------------------------------------------- --------- --------- ---- ---
  *PACS1*      p.Arg203              NP_060496.2      6          3023              0              17689                                                4         26166     10   8

  *PPP2R5D*    p.Glu198              NP_006236.1      4          3023              1              17689                                                3         26166     7    4

  *SCN2A*      p.Arg937              NP_001035232.1   3          3023              0              17689                                                5         26166     8    5

  *DEAF1*      p.Gln264              NP_066288.2      2          3023              0              17689                                                7         26166     9    5

  *ALG13*      p.Asn107              NP_060936.1      5          3023              0              17689                                                1         26166     6    5

  *GRIA1*      p.Ala636              NP_000818.2      2          3023              0              17689                                                5         26166     7    4

  *COL4A3BP*   p.Ser260              NP_001123577.1   3          3023              0              17689                                                2         26166     5    3

  *SCN8A*      p.Gly214-p.Asn215     NP_055006.1      3          169               0              11631                                                1         20108     4    3

  *DEAF1*      p.Leu219-p.Gly220     NP_066288.2      2          169               0              11631                                                2         20108     4    3

  *SATB2*      p.Arg399-p.Glu402     NP_001165988.1   2          169               0              11631                                                3         20108     5    3

  *PPP2R1A*    p.Arg182              NP_055040.2      2          3023              0              17689                                                2         26166     4    3

  *SCN8A*      p.Arg1617-p.Gly1625   NP_055006.1      2          169               0              11631                                                2         20108     4    3

  *PTPN11*     p.Gly503              NP_002825.3      3          3023              0              17689                                                6         26166     9    3

  *STXBP1*     p.Gly544              NP_001027392.1   2          3023              0              17689                                                5         26166     7    3

  *BCL11A*     p.Thr47-p.Cys48       NP_075044.2      2          169               0              11631                                                4         20108     6    2

  *KCNQ3*      p.Arg230              NP_004510.1      2          3023              0              17689                                                3         26166     5    3

  *TRRAP*      p.Trp1848             NP_003487.1      2          3023              2              17689                                                9         26166     11   3

  *CLTCL1*     p.Val641-p.Asn647     NP_009029.3      2          169               0              11631                                                2         20108     4    2

  *TRPM7*      p.Thr379-p.Glu387     NP_060142.3      2          169               0              11631                                                2         20108     4    2

  *SCN2A*      p.Arg853              NP_001035232.1   2          3023              1              17689                                                2         26166     4    2

  *DUSP15*     p.Thr4                NP_001012662.1   2          3023              0              11113                                                3         19590     5    2

  *SCN2A*      p.Arg379              NP_001035232.1   2          3023              0              17689                                                6         26166     8    2

  *SATB2*      p.Val381-p.Arg389     NP_001165988.1   2          169               0              11631                                                1         20108     3    2

  *SMAD4*      p.Ile500              NP_005350.1      2          3023              0              17689                                                6         26166     8    4

  *SLC35C2*    p.Ser173-p.Gly176     NP_057029.8      2          169               0              11631                                                3         20108     5    2

  *CLCN4*      p.Arg718              NP_001821.2      2          3023              1              17689                                                4         26166     6    2

  *PCGF2*      p.Pro65               NP_009075.1      2          3023              0              17689                                                5         26166     7    2

  *KAT6B*      p.Ser1380-p.Glu1389   NP_001243398.1   2          169               0              11631                                                4         20108     6    2

  *TRIO*       p.Pro1461             NP_009049.2      2          3023              0              17689                                                1         26166     3    2

  *NCAN*       p.Pro1219-p.Val1221   NP_004377.2      2          169               0              11631                                                8         20108     10   2

  *ITPR1*      p.Thr267-p.Arg269     NP_001161744.1   2          169               0              11631                                                1         20108     3    2

  *CUX2*       p.Glu590              NP_056082.2      2          3023              1              17689                                                3         26166     5    2

  *ZNF215*     p.Arg473              NP_037382.2      2          3023              1              11113                                                10        19590     12   2

  *SMARCA2*    p.Arg525              NP_003061.3      2          3023              0              17689                                                3         26166     5    2

  *TBR1*       p.Trp271              NP_006584.1      1          3023              0              17689                                                3         26166     4    1

  *PDCD11*     p.Arg964              NP_055791.1      1          3023              0              17689                                                8         26166     9    1

                                                                                                                                                                                

  **TOTAL**    **83**                                 **7**                        **139**                                                             **222**   **101**        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Minor allele frequency (MAF) \< 0.01% in ExAC v.0.3 and ESP v.0.0.30.

denovo-db v.0.9 and smMIPs.

[^1]: Present address: Department of Pharmacology, Creighton University School of Medicine, Omaha, Nebraska, USA
